(WFRF:(Swedin Agneta))
Search: (WFRF:(Swedin Agneta)) > Improved survival i...
- 4 of 8
- Previous record
- Next record
- To hitlist
Improved survival in myeloma patients : starting to close in on the gap between elderly patients and a matched normal population
- Liwing, Johan (author)
-
- Uttervall, Katarina (author)
- Karolinska Institutet
-
- Lund, Johan (author)
- Karolinska Institutet
- show more...
- Aldrin, Anders (author)
- Blimark, Cecilie (author)
- Enestig, Jon (author)
- Flogegård, Max (author)
- Gruber, Astrid (author)
- Johansson, Peter (author)
- Lauri, Birgitta (author)
- Mellqvist, Ulf-Henrik (author)
- Swedin, Agneta (author)
- Svensson, Magnus (author)
- Aschan, Johan (author)
- show less...
- (creator_code:org_t)
- 2013-12-09
- 2014
- English.
- In: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 164:5, s. 684-693
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- The outcome for multiple myeloma patients has improved since the introduction of bortezomib, thalidomide and lenalidomide. However, studies comparing new and conventional treatment include selected patient groups. We investigated consecutive patients (n = 1638) diagnosed in a defined period and compared survival with a gender- and age-matched cohort Swedish population (n = 9 340 682). Median overall survival for non-high-dose treated patients was 2.8 years. The use of bortezomib, thalidomide or lenalidomide in first line therapy predicted a significantly longer overall survival (median 4.9 years) compared to conventional treatment (2.3 years). Among non-high-dose treated patients receiving at least 2 lines with bortezomib, thalidomide or lenalidomide, 69% and 63% have survived at 3 and 5 years as compared to 48% and 22% with conventional drugs and 88% and 79% in the matched cohort populations, respectively. The median overall survival in high-dose treated patients was 6.9 years. Of these patients, 84% survived at 3 years and 70% at 5 years as compared to 98% and 95% in the matched cohort population. Overall survival in the best non-high-dose treated outcome group is closing the gap with the matched cohort. Upfront use of new drugs is clearly better than waiting until later lines of treatment.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- myeloma
- time to next treatment
- progression-free survival
- treatment sequencing
- population based
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- British Journal of Haematology (Search for host publication in LIBRIS)
To the university's database
- 4 of 8
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Liwing, Johan
- Uttervall, Katar ...
- Lund, Johan
- Aldrin, Anders
- Blimark, Cecilie
- Carlson, Kristin ...
- show more...
- Enestig, Jon
- Flogegård, Max
- Forsberg, Karin
- Gruber, Astrid
- Kviele, Helene H ...
- Johansson, Peter
- Lauri, Birgitta
- Mellqvist, Ulf-H ...
- Swedin, Agneta
- Svensson, Magnus
- Näsman, Per
- Alici, Evren
- Gahrton, Gösta
- Aschan, Johan
- Nahi, Hareth
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Hematology
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- British Journal ...
- By the university
- Royal Institute of Technology
- Karolinska Institutet
- Umeå University
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
